Zacks Investment Research on MSN

ZBIO tanks despite positive data from rare autoimmune diseases study

Zenas BioPharma ZBIO announced that the phase III INDIGO study, which evaluated its lead pipeline candidate, obexelimab, for treating patients with immunoglobulin G4-related disease (IgG4-RD), has met ...
Business Insider

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma First data from Phase 1 trial show the safety and tolerability ...
BioSpace

Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...
Seeking Alpha

Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript

Good morning, everyone. Welcome to the Zenas Biopharma Conference Call. [Operator Instructions] Be advised that this call is being recorded at the company's request, and a replay will be available in ...